Clinical Research Directory
Browse clinical research sites, groups, and studies.
Transcatheter Self-expandable Valve Implantation for the Treatment of Severe Native Aortic Regurgitation
Sponsor: Nanjing First Hospital, Nanjing Medical University
Summary
Prospective, multicenter, randomized trial.
Official title: Transcatheter Self-expandable Valve Implantation for the Treatment of Severe Native Aortic Regurgitation: a Prospective, Multicenter, Randomized Study
Key Details
Gender
All
Age Range
60 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
210
Start Date
2021-05-21
Completion Date
2031-05-30
Last Updated
2026-04-08
Healthy Volunteers
No
Conditions
Interventions
Transcatheter Aortic Valve Implantation
The VitaFlow™ system (MicroPort®, Shanghai, China) was a novel TAVR system, which incorporates high-radial force and a double layer polyethylene terephthalate (PET) skirt to optimize frame geometry and minimize the risks of paravalvular leak (PVL). The VitaFlow™ transcatheter aortic valve is made of a self-expanding nitinol frame and tri-leaflet bovine pericardial valve.
Medical therapy
Angiotensin-neprilysin inhibition (ARNI), diuretics, dihydropyridine calcium channel blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) or beta blockers.
Locations (1)
Nanjing First Hospital
Nanjing, Jiangsu, China